The efficacy of TCZ in iMCD has been evaluated in an open-label trial in Japan using inflammatory markers (CRP, fibrinogen, and erythrocyte sedimentation rate), with general malaise measured using VAS, Hb, and hypoalbuminemia.[20] The CHAP score was proposed as an index to evaluate the disease activity of iMCD,[10] The components of the CHAP score are CRP, Hb, Alb, and Eastern Cooperative Oncology Group Performance Status, which are similar to the evaluation items used to evaluate the effectiveness of TCZ. The gene discussed is ALB; the disease is Hypoalbuminemia.